These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 24274399)

  • 1. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.
    Holder SL; Abdulkadir SA
    Curr Cancer Drug Targets; 2014; 14(2):105-14. PubMed ID: 24274399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
    Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
    Kim J; Roh M; Abdulkadir SA
    BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
    Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS
    Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.
    Ha S; Iqbal NJ; Mita P; Ruoff R; Gerald WL; Lepor H; Taneja SS; Lee P; Melamed J; Garabedian MJ; Logan SK
    Oncogene; 2013 Aug; 32(34):3992-4000. PubMed ID: 22986532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIM1 kinase as a target for cancer therapy.
    Merkel AL; Meggers E; Ocker M
    Expert Opin Investig Drugs; 2012 Apr; 21(4):425-36. PubMed ID: 22385334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
    Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of quinones as novel PIM1 kinase inhibitors.
    Schroeder RL; Goyal N; Bratton M; Townley I; Pham NA; Tram P; Stone T; Geathers J; Nguyen K; Sridhar J
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3187-3191. PubMed ID: 27173800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
    Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
    PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction.
    Ye C; Zhang C; Huang H; Yang B; Xiao G; Kong D; Tian Q; Song Q; Song Y; Tan H; Wang Y; Zhou T; Zi X; Sun Y
    Cell Physiol Biochem; 2018; 48(3):1230-1244. PubMed ID: 30045021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells.
    Zemskova M; Sahakian E; Bashkirova S; Lilly M
    J Biol Chem; 2008 Jul; 283(30):20635-44. PubMed ID: 18426800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.
    Shah N; Pang B; Yeoh KG; Thorn S; Chen CS; Lilly MB; Salto-Tellez M
    Eur J Cancer; 2008 Oct; 44(15):2144-51. PubMed ID: 18715779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights from Pim1 structure for anti-cancer drug design.
    Ogawa N; Yuki H; Tanaka A
    Expert Opin Drug Discov; 2012 Dec; 7(12):1177-92. PubMed ID: 23004574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review).
    Magadoux L; Isambert N; Plenchette S; Jeannin JF; Laurens V
    Int J Oncol; 2014 Sep; 45(3):919-28. PubMed ID: 24969394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.